Neumora Therapeutics
antagonist broad potential across neuropsychiatric disorders i | Neumora Therapeutics
Company
Deck Type
IPO
Sector
Industry
Deck date
September 2023
Slide
17 of 32
Related slides by other companies
argenx SE
Investor Presentation
November 2023
musk agonist with broad potential in neuromuscular disease clinical | argenx SE
Kymera
Investor Presentation
December 2023
oral agent with potential to achieve broad well tolerated anti inflammatory effect in multiple diseases | Kymera
Ocuphire Pharma
Investor Presentation
November 2023
a new differentiated and combination therapy offers pos potential other cholinergic bay alpha antagonist alpha favorable safety tolerability no broad range of patients dose | Ocuphire Pharma
Poseida Therapeutics
IPO
July 2020
program has broad potential in multiple indications | Poseida Therapeutics
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io